NCT06543940 Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane
| NCT ID | NCT06543940 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mahidol University |
| Condition | AKI - Acute Kidney Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 8 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 8 participants in total. It began in 2024-09-01 with a primary completion date of 2025-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (CRRT) with the oXiris membrane. This membrane offers the added benefit of absorbing inflammatory cytokines. In vitro studies show that vancomycin is reduced by around 20 percent in patients using the AN69ST membrane, which is part of the oXiris membrane's structure. However, there is currently a lack of in vivo studies demonstrating the impact of the oXiris membrane on vancomycin levels. Therefore, the hypothesis of this study is that vancomycin is also reduced by absorption in the oXiris membrane. This study measures the levels of vancomycin in these patients to determine the pharmacokinetic parameters.
Eligibility Criteria
Inclusion Criteria: * Patients aged more than 18 years. * Admitted to the intensive care unit of Ramathibodi Hospital. * Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter. * Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter. * who have signed the informed consent document. Exclusion Criteria: * Patients with a history of vancomycin allergy. * Patients expected to die within 24 hours after inclusion in study. * Patients with circuit clotting occurring more than 2 hours during the blood draw period. * Patients treated with extracorporeal membrane oxygenation (ECMO). * Patients with a history of kidney transplantation. * Pregnant or breastfeeding women. * Patients who have decided to receive palliative care. * Patients on hemodialysis or peritoneal dialysis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06543940 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying AKI - Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06543940 currently recruiting?
Yes, NCT06543940 is actively recruiting participants. Contact the research team at chidtawan.hir@mahidol.ac.th for enrollment information.
Where is the NCT06543940 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT06543940 clinical trial?
NCT06543940 is sponsored by Mahidol University. The trial plans to enroll 8 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.